Infectious Disease Phase 2 Deal Benchmarks — US Only

Understanding Infectious Disease Deal Benchmarks at Phase 2

Phase 2 Infectious Disease licensing deals in US Only territory command a median upfront payment of $282M, with values ranging from $162M at the low end to $434M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $752M to $1.5B, with a median of $1.1B. Royalty rates for infectious disease assets at this stage typically fall between 6.5% and 13% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.